LARRY ROBBINS

Larry Robbins grew up in Evanston, Illinois, and showed early signs of being wired differently than most people. He was the kind of kid who found finance genuinely interesting rather than just profitable, which is a rarer trait than it sounds.

He went to the University of Pennsylvania's Wharton School — one of the most competitive undergraduate business programs in the world — and graduated in 1992. From there he landed at Leon Cooperman's Omega Advisors, one of the most respected value-oriented hedge funds of that era.

Cooperman was the kind of mentor who could turn a sharp mind into a genuine investor, and Robbins absorbed as much as he could.

In 2001, he left to start Glenview Capital Management. This was not an obvious time to launch a hedge fund — the dot-com bust was still reverberating and institutional capital was nervous.

Robbins started small and built carefully.

The strategy that defined Glenview was deceptively simple: find industries undergoing structural change, develop a deeper analytical edge than anyone else in that space, and hold with conviction. Healthcare became his primary hunting ground.

He studied hospitals, managed care organizations, pharmaceutical companies, and medical device makers with an intensity that bordered on obsessive. By the time most investors understood a healthcare story, Robbins had been living inside it for months.

Glenview peaked at over $10 billion in assets under management in the mid-2010s, making it one of the larger healthcare-focused hedge funds in the world. Robbins was regularly cited as one of the most successful and respected long/short equity managers of his generation.

Then 2015 hit. The Affordable Care Act trade — which had made Glenview famous and very rich — started unwinding.

Managed care and hospital stocks, which Robbins had loaded up on anticipating the ACA's expansion of coverage, sold off sharply. Glenview lost approximately 18% that year.

For a fund of its size, that was a serious blow.

Robbins's response was remarkable. He wrote a long, unflinching letter to his investors taking full responsibility.

More concretely, he returned roughly $100 million in fees to clients out of his own pocket. Not because he was legally required to — he wasn't.

Because he thought it was the right thing to do. It became one of the most talked-about acts of accountability in modern hedge fund history.

He rebuilt. Glenview eventually returned to profitability, and Robbins continued running the fund into the 2020s, though at a somewhat smaller scale than its peak.

His reputation, battered by 2015, was substantially restored by both his returns and his character.

He has also been deeply involved in philanthropy, particularly focused on education reform and children's causes — a commitment that has become as central to his public identity as his investment record.

Glenview Capital Management is the whole story. Robbins founded it in 2001 in New York City with modest initial capital and built it into one of the most prominent healthcare-focused hedge funds in the world.

At its peak, the fund managed north of $10 billion across long and short equity positions, primarily in U.S. and global healthcare companies but also in other sectors undergoing significant structural change.

Glenview's approach is fundamentally long/short equity — they buy stocks they think are undervalued and short stocks they think are overvalued, with the goal of making money in both directions and reducing the fund's overall sensitivity to market swings. In practice, Glenview has historically run with a net long bias, meaning they bet more on stocks going up than going down.

The fund's most famous trade was its massive bet on managed care companies and hospital operators ahead of the Affordable Care Act's implementation. Glenview identified early that the ACA would dramatically expand insurance coverage, which would be enormously positive for hospital systems treating uninsured patients who couldn't pay.

They built enormous positions in companies like HCA Holdings, Tenet Healthcare, and major managed care insurers. That trade made the fund — and its investors — a great deal of money.

Beyond healthcare, Glenview has taken significant positions in financial services, industrial companies, and other sectors where Robbins believed the market was misunderstanding the structural story. He's not locked into healthcare — he's locked into thesis-driven investing wherever the opportunity is clearest.

Robbins has served on the boards of several portfolio companies, which reflects the engaged-ownership approach that characterizes his style. He doesn't just buy stocks and wait — he gets involved.

Larry Robbins is a thesis investor. That means he doesn't buy stocks — he buys arguments.

Before he puts a dollar into anything, he wants to understand exactly why the market is wrong about this company, what the structural change is that other people aren't seeing, and what the path looks like for the stock to reflect that reality. If he can't articulate a clear thesis, he doesn't buy.

Think of it like this: most investors look at a company the way a tourist looks at a city — they see the surface, the highlights, the things everyone already knows. Robbins tries to live in the city.

He wants to understand the plumbing, the politics, the local economy — things that take months of work to understand properly. By the time he's ready to build a position, he typically knows the company better than most of its own employees.

Healthcare is his chosen territory, and for good reason. Healthcare is one of the most complex industries in America — it's heavily regulated, politically sensitive, and prone to enormous structural shifts that take years to play out.

That complexity is actually an advantage for an investor willing to do the deep work, because most market participants give up and stick to simpler sectors. Robbins leaned into the complexity.

His ACA trade is the best illustration. When the Affordable Care Act passed in 2010, most investors weren't sure what to make of it.

The political noise was deafening. Robbins cut through that and focused on the economics: millions of previously uninsured Americans would now have coverage.

Hospitals, which had been absorbing billions in uncompensated care, would now get paid. That was a structural shift with a clear financial consequence.

He built enormous positions in hospital stocks and managed care companies years before the trade fully played out. When it did, Glenview made extraordinary returns.

He runs a concentrated book — he doesn't believe in owning 200 stocks. He'd rather own 25 things he understands deeply than 100 things he understands superficially.

High conviction, deep research, willingness to hold. That's the Robbins playbook.

He also runs short positions, which is another layer of complexity. Glenview bets against companies it believes are structurally deteriorating — overhyped businesses with declining fundamentals.

Getting shorts right requires a different kind of analysis and a different kind of patience, and it's an area where many long/short funds quietly underperform. Robbins takes it seriously.

The ACA trade is the defining win of Robbins's career. Starting around 2010 and accelerating through 2013 and 2014, Glenview built massive positions in hospital operators and managed care companies based on a single, well-reasoned thesis: the Affordable Care Act would dramatically expand insurance coverage in America, which would be profoundly positive for companies that had been eating billions in uncompensated care.

Most investors were paralyzed by the political noise around the ACA. Would it survive court challenges?

Would Republicans repeal it? Was this even a real policy or just a law that would never fully implement?

Robbins cut through all of that and focused on what he could analyze: the economics. If this law works as written, here's what happens to hospital margins.

Here's what happens to managed care enrollment. Here's the math.

He was early and he was large. Glenview owned enormous positions in HCA Holdings, Tenet Healthcare, and major managed care insurers.

When the Supreme Court upheld the ACA in 2012 and implementation began in earnest in 2013 and 2014, those stocks moved dramatically. Hospital stocks were up 50%, 60%, 70% over that period.

Managed care companies performed similarly.

Glenview's returns during 2013 were reported to be among the best of any major hedge fund that year — the fund reportedly returned over 80% gross. That's not a typo.

It was a combination of the right thesis, the right sizing, and the patience to hold through the noise. The ACA trade turned Glenview from a successful fund into a famous one.

It also demonstrated something important about Robbins's edge: he was willing to have a strong opinion on a politically complex question when most of his peers were too uncomfortable to engage with it seriously.

The mirror image of the ACA win is the 2015 loss. The same healthcare sector that made Glenview famous almost broke it.

The problem was partly that a thesis that had worked beautifully for four years was now playing out differently than Robbins had modeled. The ACA did expand coverage — he was right about that.

But the managed care companies faced more pricing pressure and regulatory friction than anticipated, and the hospitals didn't benefit as uniformly as the model suggested. Meanwhile, the market started pricing in political risk around ACA repeal more aggressively.

Glenview's large, concentrated healthcare positions — the exact positions that had produced such extraordinary gains — now worked against the fund. When the thesis started to crack, there was nowhere to hide.

The fund lost approximately 18% in 2015. On a multi-billion dollar fund, that's a staggering absolute dollar loss for investors.

What made it worse was that Glenview had been so right for so long. Investors had come to think of the fund as a machine, not a bet.

The 2015 loss was a reminder that concentrated conviction can produce spectacular losses as easily as spectacular gains.

Robbins's response was the right one, but it doesn't erase the cost. He returned roughly $100 million in fees voluntarily, wrote a searingly honest letter to investors, and then had to rebuild trust over several years.

The fund shrank significantly as some investors redeemed.

The lesson he drew publicly was about the difference between being right about a structural trend and being right about timing and sizing. He was right that the ACA would change healthcare.

He was too concentrated and too slow to recognize when the trade had run its course.

Robbins's core belief is that markets are mostly efficient but occasionally wildly wrong, and the windows of inefficiency are widest in complex industries that most investors don't bother to understand. His job is to find those windows and climb through them before they close.

He believes in earned conviction. That means you only get to have strong opinions about stocks you've done strong work on.

Generic views, lazy analysis, surface-level research — those don't earn you the right to bet big. The research has to come before the conviction, not the other way around.

He's deeply committed to intellectual honesty. When 2015 went wrong, he didn't construct a narrative that blamed external forces.

He looked at what he got wrong — specifically, that the ACA's implementation created more pricing pressure in managed care than he'd anticipated — and he said so plainly. That kind of post-mortem is rare in the hedge fund world, where the incentive is always to spin losses as temporary and recoverable.

Robbins also believes strongly in alignment of interests. The reason he returned fees in 2015 was that he didn't feel he'd earned them — and he wanted his investors to know that he'd never take their money for granted.

He runs the fund like he's a partner, not a service provider.

On position sizing, he has a simple principle: bet big when you're most sure, bet small when you're less sure, and never let a single position become so large that being wrong about it ends the fund. Conviction should drive position size, but paranoia should cap it.

And he genuinely believes in the power of long time horizons to let theses play out. Wall Street is structurally short-term — quarterly earnings cycles, redemption pressure, career risk from short-term underperformance.

Robbins has tried to build a fund and an investor base that can be patient. That patience is itself a competitive advantage.

Robbins is married and has children, though he keeps his family life genuinely private — there's not much in the public record beyond that. For a man of his wealth and prominence, the relative scarcity of personal detail in his press coverage suggests an intentional choice to protect that space.

What is public is his deep commitment to causes that relate to children — both in his philanthropy focused on educational opportunity and in his support for pediatric medical causes. That consistency between professional focus on healthcare and personal giving toward children's wellbeing suggests someone whose values and work are genuinely integrated rather than compartmentalized.

He's based in New York, which is where Glenview operates, and has been a fixture of the city's philanthropic community for years.

Robbins attended the University of Pennsylvania's Wharton School, graduating in 1992 with a degree in economics. Wharton's undergraduate program is one of the most competitive business programs in the country, and it gave him a rigorous quantitative foundation that shows up in the analytical depth of Glenview's research process.

He went directly into finance after graduation rather than business school, which means he learned the real craft on trading floors and in portfolio management, not in a classroom.